Last reviewed · How we verify

Matching placebo to Quetiapine XR

Janssen Research & Development, LLC · Phase 3 active Small molecule

Matching placebo to Quetiapine XR is a Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 3 development for Control arm in Phase 3 clinical trials of Quetiapine XR (schizophrenia, bipolar disorder, or major depressive disorder, depending on the specific trial).

This is a matching placebo formulation designed to mimic Quetiapine XR (an atypical antipsychotic) for blinded clinical trial purposes.

This is a matching placebo formulation designed to mimic Quetiapine XR (an atypical antipsychotic) for blinded clinical trial purposes. Used for Control arm in Phase 3 clinical trials of Quetiapine XR (schizophrenia, bipolar disorder, or major depressive disorder, depending on the specific trial).

At a glance

Generic nameMatching placebo to Quetiapine XR
SponsorJanssen Research & Development, LLC
ModalitySmall molecule
Therapeutic areaPsychiatry
PhasePhase 3

Mechanism of action

Matching placebos are inert formulations manufactured to be identical in appearance, taste, and administration schedule to the active drug being tested, enabling double-blind study designs. In this case, the placebo matches Quetiapine XR, an extended-release atypical antipsychotic that antagonizes dopamine and serotonin receptors. The placebo itself contains no active pharmaceutical ingredient and serves as the control arm in Phase 3 trials.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Matching placebo to Quetiapine XR

What is Matching placebo to Quetiapine XR?

Matching placebo to Quetiapine XR is a Small molecule drug developed by Janssen Research & Development, LLC, indicated for Control arm in Phase 3 clinical trials of Quetiapine XR (schizophrenia, bipolar disorder, or major depressive disorder, depending on the specific trial).

How does Matching placebo to Quetiapine XR work?

This is a matching placebo formulation designed to mimic Quetiapine XR (an atypical antipsychotic) for blinded clinical trial purposes.

What is Matching placebo to Quetiapine XR used for?

Matching placebo to Quetiapine XR is indicated for Control arm in Phase 3 clinical trials of Quetiapine XR (schizophrenia, bipolar disorder, or major depressive disorder, depending on the specific trial).

Who makes Matching placebo to Quetiapine XR?

Matching placebo to Quetiapine XR is developed by Janssen Research & Development, LLC (see full Janssen Research & Development, LLC pipeline at /company/johnson-johnson).

What development phase is Matching placebo to Quetiapine XR in?

Matching placebo to Quetiapine XR is in Phase 3.

Related